Extended Data Table 1 Peak expansion, exposure kinetics, MRD status, and clinical responses of ESO-T01–generated CAR-T cells

From: In vivo generation of anti-BCMA CAR-T cells in relapsed or refractory multiple myeloma: a phase 1 study

  1. CAR-T expansion was quantified by qPCR at serial timepoints after infusion. Peak levels and total exposure (area under the curve, AUC) from day 0 to day 28 were calculated. Minimal residual disease (MRD) was assessed by multiparameter flow cytometry, and clinical responses were evaluated according to International Myeloma Working Group (IMWG) consensus criteria.
  2. Abbreviations: AUC, area under the curve; CAR, chimeric antigen receptor; CR, complete response; IMWG, International Myeloma Working Group; MRD, minimal residual disease; NA, not applicable; NE, not estimable; PR, partial response; qPCR, quantitative polymerase chain reaction; sCR, stringent complete response; VGPR, very good partial response.
Back to article page